Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

References

• Bainbridge JL, Corboy JR. Multiple sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, eds. Pharmacotherapy: a pathophysiologic approach, 7th edn. New York, NY: McGraw-Hill Companies, Inc, 2008. p. 913-26
   Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ghushchyana V, Brett McQueena R, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord 2014;3:227-36
   PubMed Web of Science ®Google Scholar
• Klevan G, Jacobsen CO, Aarseth JH, et al. Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurolog Scand 2014;129:21-6
   PubMed Web of Science ®Google Scholar
• McDowell TY, Amr S, Langenberg P, et al. Time of birth, residential solar radiation and age at onset of multiple sclerosis. Neuroepidemiology 2010;34:238-44
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012;135:1778-85
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Atlas: Multiple Sclerosis Resources in the World. 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf. Accessed November 2, 2014
   Google Scholar
• Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res 2012;73:411-17
   PubMed Web of Science ®Google Scholar
• Hanson KA, Agashivala N, Wyrwich KW, et al. Treatment selection and experience in multiple sclerosis: survey of neurologists. Patient Prefer Adher 2014;8:415-22
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. Treating MS: Medications. 2015. http://www.nationalmssociety.org/Treating-MS/Medications. Accessed March 2, 2015
   Google Scholar
• The Express Scripts Lab. The 2014 Drug Trend Report. 2015. http://lab.express-scripts.com/drug-trend-report/. Accessed March 26, 2015
   Google Scholar
• Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 2011;11:122
   PubMed Web of Science ®Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. JMCP 2013;19(1 Suppl A):S24-40
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol Off J Eur Fed Neurol Soc 2011;18:69-77
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Invest 2010;30:89-100
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13:657-65
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. PharmacoEconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522; discussion 522
   PubMed Web of Science ®Google Scholar
• Cooper K, Bryant J, Harris P, et al. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a single technology appraisal. Evidence Review Group Report commissioned by the NIHR HTA Programme on behalf of NICE. The Southampton Health Technology Assessments Centre (SHTAC), 2013. https://www.nice.org.uk/guidance/ta312/documents/multiple-sclerosis-relapsingremitting-alemtuzumab-evaluation-report3. Accessed November 2, 2014
   Google Scholar
• CRD and CHE Technology Assessment Group. Fingolimod for the treatment of relapsing remitting multiple sclerosis. Evidence Review group report by the Centre for Reviews and Dissemination and Centre for Health Economics Technology Assessment Group 6 September. 2011. http://www.nice.org.uk/guidance/ta254/documents/multiple-sclerosis-relapsingremitting-fingolimod-appraisal-consultation-evidence-review-group-report2. Accessed September 4, 2014
   Google Scholar
• Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost-effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Evidence Review Group Report commissioned by NHS R&D HTA Programme on behalf of: NICE. 2007. https://www.nice.org.uk/guidance/ta127/documents/multiple-sclerosis-natalizumab-evaluation-report-evidence-review-group-report2. Accessed September 4, 2014
   Google Scholar
• Lee S, Baxter DC, Limone B, et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ 2012;15(6):1088-1096.
   PubMedGoogle Scholar
• Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. Jul 26 2011;77:355-63
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health J Int Soc Pharmacoecon Outcomes Res 2004;7:554-68
   Web of Science ®Google Scholar
• Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. p. 214-46
   Google Scholar
• ADVANCE trial. Data on file.
   Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46
   Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health J Int Soc Pharmacoecon Outcomes Res 2007;10:54-60
   Web of Science ®Google Scholar
• Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurolog Scand 1982;65:248-66
   PubMed Web of Science ®Google Scholar
• Tolley K, Hutchinson M, You X, et al. a network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon Beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One 2015;10:e0127960
   PubMed Web of Science ®Google Scholar
• Wong J, Gomes T, Mamdani M, et al. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci J Can Sci Neurolog 2011;38:429-33
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review. Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis [Internet]. Ottawa: The Agency, 2013. (CADTH Therapeutic Review vol.1, no. 2b). https://www.cadth.ca/sites/default/files/pdf/TR0004_RRMS_ScienceReport_e.pdf. Accessed June 9, 2014
   Google Scholar
• Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Therapeut 2007;29:2031-48
   PubMed Web of Science ®Google Scholar
• Ebers GC, Rice G, Lesaux, J, et al. Randomised double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler May 2014;20:705-16
   PubMed Web of Science ®Google Scholar
• Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2012;18:418-24
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
   PubMed Web of Science ®Google Scholar
• O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327-40
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-7
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14
   PubMed Web of Science ®Google Scholar
• 2010 United States Life Tables. Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany), www.mortality.org or www.humanmortality.de. Accessed February 23, 2014
   Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
   PubMedGoogle Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• United States Department of Labor. Bureau of Labor Statistics. Consumer Price Index. 2014, http://www.bls.gov/home.htm. Accessed March 31, 2014
   Google Scholar
• Barendregt JJ. The life table method of half cycle correction: getting it right. Med Decis Making Int J Soc Med Decis Making 2014;34:283-5
   PubMed Web of Science ®Google Scholar
• Getsios D, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. PharmacoEconomics 2010;28:411-27
   PubMed Web of Science ®Google Scholar
• Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications. PharmacoEconomics 2009;27:39-53
   PubMed Web of Science ®Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health J Int Soc Pharmacoecon Outcomes Res 2011;14:417-28
   Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health J Int Soc Pharmacoecon Outcomes Res 2011;14:429-37
   Web of Science ®Google Scholar
• Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2014;
   Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013;73:705-13
   PubMed Web of Science ®Google Scholar
• Red Book. Red Book For Windows. 2014
   Google Scholar
• Mathis AS, Owens GM. Implications for multiple sclerosis in the era of the Affordable Care Act: the shifting managed care landscape. Am J Manag Care 2014;20(11 Suppl):s242-53
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Physician Fee Schedule - National Payment Amount - Non-Facility Price. 2014. http://www.cms.gov/apps/physician-fee-schedule/overview.aspx. Accessed March 2, 2015
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Clinical Diagnostic Laboratory Fee Schedule. 2014. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed March 2, 2015
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Natalizumab costing template and report. Technology Appraisal Guidance TA127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. 2007. http://www.nice.org.uk/guidance/ta127/costing. Accessed September 4, 2014
   Google Scholar